Clinical trial · Interventional
Chemotherapy in Treating Patients With Cancer of Unknown Primary Origin
A Randomized Phase III Trial of Paclitaxel, Carboplatin and Etoposide Vs. 5-Fluorouracil and Folinic Acid in the Treatment of Patients With Adenocarcinoma of Unknown Primary Site
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known which combination chemotherapy regimen is more effective for cancer of unknown primary origin. PURPOSE: Randomized phase III trial to compare the effectiveness of two different regimens of combination chemotherapy in treating patients with cancer of unknown primary origin.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Carcinoma of Unknown Primary | Carcinoma of Unknown Primary | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (5)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| carboplatin | Drug | Carboplatin | ALIAS |
| etoposide | Drug | Etoposide | ALIAS |
| fluorouracil | Drug | Fluorouracil | ALIAS |
| leucovorin calcium | Drug | Leucovorin | ALIAS |
| paclitaxel | Drug | Paclitaxel | ALIAS |
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS:
* Histologically confirmed adenocarcinoma of any differentiation grade
* Excludes the following "treatable" conditions:
* Axillary node involvement
* Peritonitis carcinomatosis
* Blastic bone metastases and/or elevated PSA
* Squamous cell cancer with cervical or inguinal presentation
* Poorly differentiated carcinoma
* Neuroendocrine tumors OR
* Tumors located in the mediastinum, retroperitoneum, or nodes
* At least one measurable metastatic site
* No brain or meningeal metastases
PATIENT CHARACTERISTICS:
Age:
* Over 18
Performance status:
* ECOG 0-2
Hematopoietic:
* Leukocyte count at least 4,000/mm3
* Thrombocyte count at least 100,000/mm3
Hepatic:
* Bilirubin less than 1.4 mg/dL
* AST and ALT less than 3 times upper limit of normal
* No cirrhosis of the liver
Renal:
* Creatinine less than 1.7 mg/dL
Cardiovascular:
* At least 3 months since myocardial infarction
* No congestive heart failure, tachydysrhythmia, or unstable angina pectoris
Other:
* Not pregnant or nursing
* Negative pregnancy test
* No active infection
* No other serious illness or medical condition
* No current or prior malignancy except nonmelanomatous skin cancer or carcinoma in situ of the cervix
PRIOR CONCURRENT THERAPY:
Biologic therapy:
* Not specified
Chemotherapy:
* No prior chemotherapy
Endocrine therapy:
* Not specified
Radiotherapy:
* At least 4 weeks since prior radiotherapy (no greater than 25% of bone marrow)
Surgery:
* Not specifiedReferences
Publications (0)
Data not yet available